

Journal Pre-proof

Prebiotics and the risk of upper digestive tract and stomach cancers: the *PrebiotiCa* study

Federica Turati, PhD, Researcher, Federica Concina, PhD, Researcher, Paola Bertuccio, PhD, Researcher, Federica Fiori, PhD, Research assistant, Maria Parpinel, ScD, Professor, Werner Garavello, MD, Full Professor, Anna Crispo, ScD, Researcher, Massimo Libra, MD, Full Professor, Eva Negri, ScD, Professor, Diego Serraino, MD, Researcher, Carlo La Vecchia, MD, Full Professor

PII: S2212-2672(23)01275-3

DOI: <https://doi.org/10.1016/j.jand.2023.07.008>

Reference: JAND 55729

To appear in: *Journal of the Academy of Nutrition and Dietetics*

Received Date: 30 December 2022

Revised Date: 10 July 2023

Accepted Date: 13 July 2023

Please cite this article as: Turati F, Concina F, Bertuccio P, Fiori F, Parpinel M, Garavello W, Crispo A, Libra M, Negri E, Serraino D, La Vecchia C, Prebiotics and the risk of upper digestive tract and stomach cancers: the *PrebiotiCa* study, *Journal of the Academy of Nutrition and Dietetics* (2023), doi: <https://doi.org/10.1016/j.jand.2023.07.008>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Copyright © 2023 by the Academy of Nutrition and Dietetics.



Article type: Research Brief

Title: Prebiotics and the risk of upper digestive tract and stomach cancers: the *PrebiotiCa* study

Keywords: Upper digestive tract cancer; Stomach cancer; Prebiotics; Fiber; Prevention.

Text word count: 2737

Abstract word count: 300

Author contact information

Federica Turati, PhD; Researcher

Branch of Medical Statistics, Biometry, and Epidemiology "G.A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milan, Via Celoria 22, 20133 Milan, Italy.

Phone: +39 0250320873; email: federica.turati@unimi.it; ORCID: 0000-0002-5841-5773

Federica Concina, PhD; Researcher

Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Via dell'Istria 65/1, 34137

Trieste, Italy.

Phone: +39 040785236; email: federica.concina@burlo.trieste.it; ORCID: 0000-0002-6777-2924

Paola Bertuccio, PhD; Researcher

Branch of Medical Statistics, Biometry, and Epidemiology "G.A. Maccacaro", Department of

Clinical Sciences and Community Health, University of Milan, Via Celoria 22, 20133 Milan, Italy

Department of Public Health, Experimental and Forensic Medicine, Via Forlanini 2, 27100

University of Pavia, Pavia, Italy.

Phone: +39 0382987284; Email: paola.bertuccio@unipv.it; ORCID: 0000-0002-2002-0127

Federica Fiori, PhD; Research assistant

Department of Medicine-DAME, University of Udine, Via Colugna 50, 33100 Udine, Italy

Email: federica.fiori@uniud.it; ORCID: 0000-0003-2886-8074

Maria Parpinel, ScD; Professor

Department of Medicine-DAME, University of Udine, Via Colugna 50, 33100 Udine, Italy.

Phone: +39 0432559602; email: maria.parpinel@uniud.it; ORCID: 0000-0003-1309-4467

Werner Garavello, MD; Full Professor

Department of Otorhinolaryngology, School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, 20900 Monza, Italy.

Phone: +39 0392333623; email: werner.garavello@unimib.it; ORCID: 0000-0002-2002-0127

Anna Crispo, ScD; Researcher

Epidemiology Unit, National Cancer Institute "Pascale Foundation" IRCCS, Via M. Semmola 1, 80131 Naples, Italy.

Phone: +39 08117770298; email: a.crispo@istitutotumori.na.it; ORCID: 0000-0002-8455-3328

Massimo Libra, MD; Full Professor

Laboratory of Translational Oncology & Functional Genomics, Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 97, 95123 Catania, Italy.

Phone: +39 0954781271; Email: mlibra@unict.it; ORCID: 0000-0002-7232-7737

Eva Negri, ScD; Professor

Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.

email: eva.negri@unibo.it; ORCID: 0000-0001-9712-8526

Diego Serraino, MD; Researcher

Unit of Cancer Epidemiology, CRO National Cancer Institute, IRCCS, via F. Gallini 2, 33080 Aviano, Italy.

Phone: +39 0434659232; Email: serrainod@cro.it; ORCID: 0000-0003-0565-8920

Carlo La Vecchia^a, MD, Full Professor

Branch of Medical Statistics, Biometry, and Epidemiology "G.A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milano, Via Celoria 22, 20133 Milan, Italy.

Phone: +39 0250320863; email: carlo.lavecchia@unimi.it; ORCID: 0000-0003-1441-897X

Author contributions

FT, CLV, FC and MP designed the research; FT defined the methodology and drafted the manuscript; PB and FT performed the statistical analyses; FC, FF and MP contributed substantially to nutritional analysis and results interpretation; WG, AC, ML, EN, DS and CLV collected data; CLV, EN and DS defined study design for the case-control studies. All authors reviewed and commented on subsequent drafts of the manuscript.

Correspondence to:

Dr Federica Turati, Branch of Medical Statistics, Biometry, and Epidemiology "G.A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milano, Via Celoria 22, 20133 Milan, Italy. Phone: +39 0250320873; email: federica.turati@unimi.it; ORCID: 0000-0002-5841-5773

Funding information: This work was supported by the Italian Ministry of Health ("PrebiotiCa" project, Ricerca Finalizzata Giovani Ricercatori, GR-2016-02361123).

Conflict of interest disclosure: The authors have no financial or non-financial interests to disclose.

1 **Prebiotics and the risk of upper digestive tract and stomach cancers: the PrebiotiCa study**

2

3 **Research snapshot**

4 *Research Question*

5 Does a diet rich in prebiotics reduce the risk of upper digestive tract and stomach cancers?

6 *Key Findings*

7 In the present investigation within the *PrebiotiCa* study, including over 1600 cancer patients from a
8 network of Italian case-control studies, a lack of association was observed between the intake of
9 fibers with recognized prebiotic activity and the risk of cancers of the oral cavity and pharynx,
10 nasopharynx and esophagus. A high intake of raffinose, a galacto-oligosaccharides, was associated
11 with reduced stomach cancer risk.

12 **Prebiotics and the risk of upper digestive tract and stomach cancers: the PrebiotiCa study**

13

14 **Abstract**

15 *Background*

16 Fiber intake may lower digestive tract cancer risk, possibly by modulating the composition of gut
17 microbiota. However, no data is available about the role of specific fiber fractions with prebiotic
18 activity, e.g., inulin-type fructans (ITFs), fructo-oligosaccharides (FOSs) and
19 galactooligosaccharides (GOSs), on the risk lower digestive tract cancer.

20 *Objective*

21 The objective was to assess the association between prebiotic intake and the risk of cancers of the
22 upper digestive tract and stomach.

23 *Design*

24 Within the PrebiotiCa study, data were derived from a network of Italian case-control studies
25 conducted between 1992 and 2009. Participants' usual diet was assessed using a food frequency
26 questionnaire (FFQ). ITFs, and selected FOSs (nystose, kestose and 1F- β -fructofuranosylnystose)
27 and GOSs (raffinose and stachyose) were quantified in several food products *via* laboratory
28 analyses. Participants' prebiotic intake was calculated by multiplying FFQ intake by the prebiotic
29 content of each food item.

30 *Participants/setting*

31 Cases were patients admitted to major hospitals with incident histologically confirmed cancers;
32 there were 946 cases of cancer of the oral cavity/pharynx, 198 of the nasopharynx, 304 of the
33 esophagus, 230 of the stomach. Over 4,000 patients admitted to the same hospitals for acute non-
34 neoplastic nor diet-related conditions were selected as controls.

35 *Main outcome measures*

36 The outcomes were oral and pharyngeal, nasopharyngeal, esophageal and stomach cancers.

37 *Statistical analyses performed*

38 The odds ratios (OR) and corresponding confidence intervals (CI) of the various cancers were
39 derived using logistic regression models adjusted for major confounders and energy intake.

40 *Results*

41 No association was observed between the intake of prebiotics and the risk of cancers of the oral
42 cavity and pharynx, nasopharynx and esophagus. High raffinose intake reduced stomach cancer risk
43 (OR for the third *versus* the first tertile 0.6, 95% confidence interval, CI: 0.3-0.9); no other prebiotic
44 was associated with stomach cancer.

45 *Conclusions*

46 The current study does not support a major role of prebiotic fibers on selected upper digestive tract
47 cancers. The association between high raffinose intake and reduced stomach cancer risk needs
48 further investigation in future studies.

49 **Prebiotics and the risk of upper digestive tract and stomach cancers: the PrebiotiCa study**

50

51 **Introduction**

52 Although various definitions of prebiotics have been proposed ^{1, 2}, the most commonly accepted is

53 that of a substrate that is selectively utilized by host microorganisms conferring health benefits ².

54 Currently established prebiotics are the fiber types galacto-oligosaccharides (GOSs) and inulin-type

55 fructans (ITFs), including fructooligosaccharides (FOSs)³. Prebiotics improve the integrity and

56 permeability of the gastrointestinal barrier, prevent pathogen colonization by raising competitive

57 pressure and by producing compounds with antibiotic or immunomodulating effects, impact

58 favorably on the immune function, and increase mineral absorption⁴. Most of these effects are

59 attributed to short-chain fatty acids (SCFAs), produced from the anaerobic fermentation of

60 prebiotics by intestinal bacteria. SCFAs, primarily acetate, propionate, and butyrate, have potent

61 anti-neoplastic properties⁵. While the strongest evidence for the protective role of SCFAs is for

62 colorectal cancer, other neoplasms may be effected, including bladder, breast, stomach, liver, lung,

63 pancreatic and prostate cancers ⁵. In particular, a study showed that butyrate and propionate induce

64 apoptosis and necrosis in gastric cancer cells *in vitro*⁶. In addition, prebiotics have dietary fiber

65 effects, e.g., bulking effects and favorable effects on glucose and lipid metabolism.

66 Several studies showed that fiber intake is associated with reduced risks of cancers of the oral cavity

67 and pharynx⁷⁻⁹, esophagus¹⁰, and stomach¹¹. Limited evidence also exists for the association of

68 dietary fiber from fresh food items with nasopharyngeal cancer¹². To our knowledge, however, no

69 study has assessed the association between the intake of specific fibers classified as prebiotics with

70 the risk of upper digestive tract and stomach cancers.

71 The prebiotics FOSs and GOSs occur naturally in diverse plant products, but food composition data

72 on these prebiotic molecules and estimates of prebiotic consumption in individuals are limited¹³⁻¹⁸.

73 The *PrebiotiCa* study was established to quantify prebiotics in commonly consumed foods and
74 associate their intake with cancer development using data from a network of Italian case-control
75 studies on various cancer sites; the study collected detailed dietary information through a
76 reproducible¹⁹ and valid²⁰ food frequency questionnaire (FFQ).

77 The present investigation assessed the association between the intake of selected fiber-type
78 prebiotics, i.e., ITFs, nystose (FOS), kestose (FOS), 1F- β -fructofuranosylnystose (FOS), raffinose
79 (GOS) and stachyose (GOS), and the risk of cancers of the upper digestive tract and the stomach
80 within the *PrebiotiCa* study.

81

82

83 **Methods**

84 *Study design and data collection*

85 Data for the *PrebiotiCa* study derived from a network of case-control studies on various neoplasms
86 conducted between the 1990's and the 2000's in various Italian areas. The present analysis focused
87 on cancers of the upper digestive tract and stomach, and included a total of 946 cases of cancer of
88 the oral cavity and pharynx (with corresponding 2492 controls)²¹, 198 of the nasopharynx (594
89 controls)²², 304 of the esophagus (743 controls)²³, and 230 of the stomach (547 controls)^{24, 25} (Table
90 1). Each cancer study has its own database, i.e., four distinct databases. Briefly, all studies included
91 incident cases, identified in the major teaching and general hospitals of the study areas. Controls
92 were patients admitted to the same network of hospitals of cases for a wide spectrum of acute,
93 nonneoplastic conditions unrelated to smoking, alcohol consumption or long-term diet
94 modification. Controls were frequency-matched with cases by age and sex in the study on stomach
95 cancer; by age, sex, period of interview, and study area in the studies on nasopharyngeal and
96 esophageal cancers; by study center and age in the study on oral and pharyngeal cancer (to
97 compensate for the rarity of oral and pharyngeal cancer in women, an overrepresentation of female
98 vs male controls was adopted). The participation rate was >95% for cases and controls in all the

99 studies. The study protocols were revised and approved by the ethical committees of the hospitals
100 involved, according to the regulations at the time of each study conduction, and all participants gave
101 informed consent.

102 Cases and controls were interviewed by centrally trained interviewers using the same structured
103 questionnaire, which included socio-demographic characteristics (e.g., education and occupation),
104 lifetime smoking habits, physical activity, anthropometric measures at various ages, a problem-
105 oriented personal medical history, and family history of cancer. Participants' usual diet in the two
106 years preceding diagnosis (for cases) or hospital admission (for controls) was assessed using a
107 reproducible¹⁹ and valid²⁰ FFQ. The FFQ asked for the average weekly consumption of 78 items
108 including foods, food groups, recipes and non-alcoholic beverages; an additional section of the
109 questionnaire addressed the consumption of alcoholic beverages typical of the Italian tradition.
110 Intakes lower than once per week, but at least once per month, were coded as 0.5 per week. Energy
111 and nutrient intakes were computed by combining FFQ data on frequency of consumption with
112 Italian food composition databases^{26,27} using standard methodology²⁸.

113

114 *Prebiotic determinations in foods*

115 The methodology used for the quantification of prebiotic fibers was described in detail elsewhere²⁹.
116 Briefly, the content of GOSs and FOSs was determined in 78 foods, most of which were assessed
117 by the FFQ used in the present network of studies: 15 types of fruits, 32 varieties of vegetables, root
118 vegetables and tubers, nine types of dried or fresh legumes, and 22 types of cereals and cereals-
119 based products (both wholegrain and refined products). ITFs were determined in seven foods: fresh
120 onion, garlic, banana, leek, Jerusalem artichoke, artichoke and shallot (all but Jerusalem artichoke
121 were assessed in the FFQ). Food sampling (from supermarkets located in Modena from 17 May to
122 24 June 2021) and analysis were conducted in a certified laboratory (for food analysis) by Neutron
123 SpA, Modena.

124 ITFs were determined using an internal analytical method based on AOAC 997.08 procedure, based
125 on an enzymatic hydrolysis and a high-performance anion-exchange chromatography coupled to
126 pulsed amperometric detection (HPAE-PAD). The limit of detection (LOD) of the methodology
127 was 0.005g / 100g. ITFs content ranged from 25.1 g/100g in garlic to 1 g/100g in onion and leek.
128 FOSs and GOSs in fresh samples were determined according to Manali Aggrawal and Jeff Rohrer
129 method based on an alkaline hydrolysis and HPAE-PAD detection (Thermo Scientific, Application
130 Note 1149: Profiling Fructosyloligosaccharides (FOS)-containing samples by HPAE-PAD.
131 Sunnyvale, CA, 2015). The following molecules were quantified: raffinose (GOS), stachyose
132 (GOS), nystose (FOS), kestose (FOS) and 1f-fructofuranosylnystose (FOS). The LOD was 0.002-
133 0.02g/100g, based on the food matrix. The principal contributor of FOSs was Jerusalem artichoke
134 (4.45 g/100g), with other foods containing less than 1 g/100 g, and was represented principally as
135 kestose. Total FOSs was calculated as the sum of nystose, kestose and 1F- β -fructofuranosylnystose.
136 The primary contributor of GOSs content was pulses, excluded green beans, with a mean content of
137 1.17 ± 0.87 g/100g. In particular, raffinose was particularly abundant in dried peas (0.498 g/100g)
138 and chickpeas (0.463 g/100 g) and stachyose in dried beans (1.905 g/100g) and peas (1.814 g/100g).

139

140 *Statistical analysis*

141 The odds ratios (OR) and the corresponding 95% confidence intervals (CI) of cancers of the oral
142 cavity and pharynx, nasopharynx and esophagus according to the intake of selected prebiotics were
143 estimated using unconditional multiple logistic regression models. For consistency with previous
144 analyses on the same database^{24, 30}, logistic regression models conditioned on age and sex were used
145 in the study on stomach cancer. On the basis of study sample, quartiles of intake were used in the
146 study on oral and pharyngeal cancer and tertiles of intake in the other studies. Tertiles or quartiles
147 were calculated based on the distributions of the intakes among controls. Prebiotics were also
148 considered as continuous variables in the models: the OR for an increment of intake equal to one
149 standard deviation, calculated after a log-transformation of the prebiotic variables, were estimated.

150 Models for the various cancer sites included the same set of covariates, but these were included
151 using different categorizations based on sample size and covariate distribution in cases and controls
152 in each cancer database. Covariates were: sex, age (5- or 10-years age groups, depending on study
153 database), study center (in categories), year of interview (continuous variable), years of education
154 (in categories, <7, 7-11, ≥ 12), alcohol drinking (in 3, 4 or 5 categories of levels of consumption),
155 tobacco smoking (in categories of never, ex, and current smokers of 2 or 3 levels of tobacco
156 consumption), body mass index (BMI) (in categories, <20, 20-24.9, 25-29.9, ≥ 30 kg/m²), and total
157 energy intake (in tertiles/quartiles/quintiles). To account for the overall dietary pattern of study
158 participants, adherence to the Mediterranean diet as measured by the Mediterranean diet score ³¹
159 was included in the models (continuous variable) as covariate. No multicollinearity was observed
160 between dietary variables derived from the same FFQ (all Pearson's correlation coefficients were
161 well below 0.8). A few missing values on adjustment factors were replaced by the median value
162 (continuous variables) or mode category (categorical variables) according to case/control status.
163 Tests for trends across quantiles were performed by including the examined variable as ordinal. In
164 case of statistically significant associations between a specific prebiotic and a specific cancer site,
165 stratified analyses were performed; effect modification was assessed using the likelihood ratio test
166 comparing models with and without interaction terms. P-values were considered significant when
167 <0.05. All analyses were conducted using SAS version 9.4³².

168

169 **Results**

170 Among control subjects, median daily intake of ITFs across study databases ranged between 679
171 [IQR: 368-1201, esophageal cancer study database] and 946 mg/day [IQR: 479-1970,
172 nasopharyngeal cancer study database]. For kestose, the median daily intake ranged between 163
173 [IQR: 127-210, oral and pharyngeal cancer study database] and 175 mg/day [IQR: 135-232,
174 nasopharyngeal cancer study database]. For nystose, the median daily intake ranged between 15
175 [IQR: 11-19 stomach cancer study database] and 16 mg/day [IQR: 13-20, nasopharyngeal cancer

176 study database]. For raffinose, the median daily intake ranged between 91 [IQR: 72-117, stomach
177 cancer study database] and 96 mg/day [IQR: 86-115, nasopharyngeal cancer study database]. For
178 stachyose, the median daily intake ranged between 175 [IQR: 98-262, esophageal cancer study
179 database] and 200 mg/day [IQR: 127-310, stomach cancer study database]; and for 1F- β -
180 fructofuranosylmaltose, the median daily intake was 2 mg/day [IQRs in all cancer databases of ~ 1-
181 6]. Kestose intake was the largest contributor of total FOSs intake (~90%); nystose (7.5-8%) and
182 1F- β -fructofuranosylmaltose intakes (2-2.5%) accounted for a small fraction of total FOSs intake
183 (data not shown).

184 Table 2 gives the OR of cancers of the upper digestive tract and of the stomach according to the
185 intakes of the various prebiotic fibers. No association was observed between the intake of prebiotics
186 and the risk of cancers of the oral cavity and pharynx, nasopharynx and esophagus. The OR of
187 stomach cancer for the third *versus* the first tertile of raffinose intake showed a decreased risk, 0.6
188 (95% CI: 0.3-0.9). In sensitivity analyses, further adjustment for total fiber intake reduced the
189 strength of the association (OR for the third *versus* the first tertile: 0.7, 95% CI: 0.4-1.2), while
190 results were nearly identical to those from the main analysis with the exclusion of extreme values
191 (i.e., observations whose distances from the IQR are greater than 1.5 times the size of the IQR)
192 (OR: 0.6, 95% CI: 0.3-0.9). The association between raffinose intake and stomach cancer was
193 similar in strata of age, sex, education, BMI, smoking, and adherence to the Mediterranean diet
194 (Figure 1). No other prebiotic was significantly associated with the neoplasm.

195

196

197 **Discussion**

198 In the present investigation within the *Prebiotica* study based on over 1600 cancer patients, no
199 association was observed between the intake of fibers with recognized prebiotic activity and the risk
200 of cancers of the upper digestive tract. For stomach cancer, a reduced risk for high intake of
201 raffinose was found; in the absence of consistent associations with the other prebiotics, in particular

202 stachyose, i.e., the other member of the GOSs family, such association needs to be interpreted with
203 caution since it may be a chance finding of multiple comparisons.

204 This is the first study to investigate the association of dietary prebiotics with the risk of cancers.

205 Within the same *Prebiotica* study, a high intake of GOSs was associated with a reduced risk of
206 colorectal³³ and laryngeal cancer³⁴.

207 According to laboratory analyses conducted within the *Prebiotica* study, GOSs were abundant in
208 legumes. Dried peas, dried chickpeas, and beans were foods with the highest raffinose content.

209 While stachyose, i.e., the other member of the GOSs family, was found in significant amounts
210 almost exclusively in legumes, raffinose-rich foods also include whole meal flour, selected whole-

211 grain based products, and barley. Raffinose was also found in white wheat flour and refined wheat
212 products, but in lower amounts than their whole counterparts. The Italian diet is rich in cereals and

213 cereal products³⁵; accounting for the amount of foods consumed, the largest contributors of
214 raffinose intake in the study population were cereal-based products, followed by legumes.

215 Legumes^{36, 37}, wholegrain cereals³⁸ and wholegrain fiber⁹ have been associated with reduced risk of
216 stomach cancer risk; their consumption, however, cannot fully explain the association between

217 raffinose and stomach cancer, in particular since legumes and wholegrain cereals have been
218 associated with lower risks of other cancers of the upper digestive tract as well, including

219 esophageal^{36, 38, 39} and oral and pharyngeal cancer^{9, 36, 39-41}, and no association was observed
220 between raffinose intake and these cancer sites. In addition to fiber, the association between higher

221 wholegrain and legume intake and lower risk of various cancers of the digestive tract is likely
222 related to the presence of antioxidants and bioactive compounds with anticarcinogenic properties^{42,}

223 ⁴³.

224 The present study has limitations and strengths. All studies included in the present analysis are
225 retrospective and hospital based. To limit selection bias, cases and controls were identified in the

226 major teaching and general hospitals of the areas under surveillance and patients admitted to
227 hospital for chronic conditions or digestive tract diseases were excluded from the control group.

228 Participation of cases and controls was satisfactory, and results were consistent across study areas.
229 The similar interview setting for cases and controls reduced information bias, and, although recall
230 bias is possible, this should not have been different based on the disease status. In addition, the FFQ
231 used in the network of studies was reproducible¹⁹ and valid²⁰. As for possible confounding,
232 estimates were adjusted for major risk factors for the neoplasms as well as for total energy intake; in
233 any case, a certain degree of residual confounding (i.e., confounding which remains despite
234 adjustment) cannot be excluded. Adjustment for Human papillomavirus (in oral and pharyngeal
235 cancer) and *Helicobacter pylori* (in stomach cancer analyses) could not be made as data were not
236 available. In a sensitivity analysis adjusting further for total fiber intake the strength of the
237 association between raffinose and stomach cancer declined. However, prebiotics are types of fiber,
238 and adjustment for total fiber intake is an over-adjustment that can bias results towards the null.

239 Estimating individual intake of prebiotics from questionnaires data is challenging and there is no
240 standard methodology for the determination of the prebiotic content of foods; in addition, the
241 definition of ITFs is not universally agreed. In particular, the FFQ used in the current study was not
242 specifically designed to assess the intake of ITFs, GOSs and FOSs. In particular, it did not include
243 items on specific dietary products reported to contain prebiotic fibers (e.g., rye products, spelt,
244 Jerusalem artichoke, breakfast cereal products, oats, soya beans) nor did it distinguish whole-grain
245 from non-wholegrain items, apart from bread. It was therefore not possible to derive participants'
246 prebiotic intake from such foods. However, intake of those foods is uncommon in the Italian
247 population, and hence their contribution to participants' daily prebiotic intake and to the prebiotic—
248 cancer associations is likely to be minimal. Because of methodological difficulties, ITFs were
249 determined in only six foods assessed by the FFQ. Garlic had by far the highest ITF content. Since
250 the FFQ did not ask a specific question about garlic intake, it was estimated based on the standard
251 amount of garlic in recipes. Assessment of garlic consumption, and hence of ITF intake, may
252 therefore be not accurate. In general, although individual estimates of prebiotics intakes may be
253 misestimated, misclassification should be balanced between cases and controls. Another limitation

254 relates to the application of results from food content analyses conducted in 2021 to dietary intakes
255 collected in the 1990s' and 2000's, since the contents of ITFs, FOSs and GOSs in food sources
256 might have changed. However, comprehensive food composition data regarding these prebiotics
257 contemporary to the time of study data collection were not available, and no prior data existed for
258 Italian food sources. The few available databases were scattered across studies conducted outside
259 Europe which applied heterogeneous methodologies for the quantification of prebiotic molecules,
260 and showed wide variation in prebiotic food composition²⁹. Further, the application of food
261 composition data to dietary data collected at a different time point, when contemporary data are not
262 available, is common in nutritional studies⁴⁴.

263

264 **Conclusions**

265 In conclusion, the current study does not support a major role of fiber-type prebiotics on the risk of
266 selected upper digestive tract cancers. The association between high raffinose intake and reduced
267 stomach cancer needs independent confirmation by larger studies.

268

269 **References**

- 270 1. Bindels LB, Delzenne NM, Cani PD, Walter J. Towards a more comprehensive concept for
271 prebiotics. *Nat Rev Gastroenterol Hepatol*. 2015;12:303-310.
- 272 2. Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: The International Scientific
273 Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope
274 of prebiotics. *Nat Rev Gastroenterol Hepatol*. 2017;14:491-502.
- 275 3. Carlson JL, Erickson JM, Lloyd BB, Slavin JL. Health Effects and Sources of Prebiotic Dietary
276 Fiber. *Curr Dev Nutr*. 2018;2:nzy005.
- 277 4. Verspreet J, Damen B, Broekaert WF, Verbeke K, Delcour JA, Courtin CM. A Critical Look at
278 Prebiotics Within the Dietary Fiber Concept. *Annu Rev Food Sci Technol*. 2016;7:167-190.
- 279 5. Mirzaei R, Afaghi A, Babakhani S, et al. Role of microbiota-derived short-chain fatty acids in cancer
280 development and prevention. *Biomed Pharmacother*. 2021;139:111619.
- 281 6. Matthews GM, Howarth GS, Butler RN. Short-chain fatty acid modulation of apoptosis in the Kato
282 III human gastric carcinoma cell line. *Cancer Biol Ther*. 2007;6:1051-1057.
- 283 7. Kawakita D, Lee YA, Gren LH, Buys SS, La Vecchia C, Hashibe M. Fiber intake and the risk of
284 head and neck cancer in the prostate, lung, colorectal and ovarian (PLCO) cohort. *Int J Cancer*.
285 2019;145:2342-2348.
- 286 8. Kawakita D, Lee YA, Turati F, et al. Dietary fiber intake and head and neck cancer risk: A pooled
287 analysis in the International Head and Neck Cancer Epidemiology consortium. *Int J Cancer*.
288 2017;141:1811-1821.
- 289 9. Kasum CM, Jacobs DR, Jr., Nicodemus K, Folsom AR. Dietary risk factors for upper aerodigestive
290 tract cancers. *Int J Cancer*. 2002;99:267-272.
- 291 10. Sun L, Zhang Z, Xu J, Xu G, Liu X. Dietary fiber intake reduces risk for Barrett's esophagus and
292 esophageal cancer. *Crit Rev Food Sci Nutr*. 2017;57:2749-2757.
- 293 11. Zhang Z, Xu G, Ma M, Yang J, Liu X. Dietary fiber intake reduces risk for gastric cancer: a meta-
294 analysis. *Gastroenterology*. 2013;145:113-120 e113.
- 295 12. Mai ZM, Ngan RK, Kwong DL, et al. Dietary fiber intake from fresh and preserved food and risk of
296 nasopharyngeal carcinoma: observational evidence from a Chinese population. *Nutr J*. 2021;20:14.
- 297 13. Muir JG, Shepherd SJ, Rosella O, Rose R, Barrett JS, Gibson PR. Fructan and free fructose content
298 of common Australian vegetables and fruit. *J Agric Food Chem*. 2007;55:6619-6627.
- 299 14. Biesiekierski JR, Rosella O, Rose R, et al. Quantification of fructans, galacto-oligosaccharides and
300 other short-chain carbohydrates in processed grains and cereals. *J Hum Nutr Diet*. 2011;24:154-176.
- 301 15. Moshfegh AJ, Friday JE, Goldman JP, Ahuja JK. Presence of inulin and oligofructose in the diets of
302 Americans. *J Nutr*. 1999;129:1407S-1411S.
- 303 16. Campbell JM, Bauer LL, Fahey GC, Hogarth A, Wolf BW, Hunter DE. Selected
304 fructooligosaccharide (1-kestose, nystose, and 1F- β -fructofuranosylnystose) composition of foods
305 and feeds. *Journal of agricultural and food chemistry*. 1997;45:3076-3082.

- 306 **17.** Anderson JL, Hedin CR, Benjamin JL, et al. Dietary intake of inulin-type fructans in active and
307 inactive Crohn's disease and healthy controls: a case-control study. *J Crohns Colitis*. 2015;9:1024-
308 1031.
- 309 **18.** van Loo J, Coussement P, de Leenheer L, Hoebregs H, Smits G. On the presence of inulin and
310 oligofructose as natural ingredients in the western diet. *Crit Rev Food Sci Nutr*. 1995;35:525-552.
- 311 **19.** Franceschi S, Negri E, Salvini S, et al. Reproducibility of an Italian food frequency questionnaire for
312 cancer studies: results for specific food items. *Eur J Cancer*. 1993;29A:2298-2305.
- 313 **20.** Decarli A, Franceschi S, Ferraroni M, et al. Validation of a food-frequency questionnaire to assess
314 dietary intakes in cancer studies in Italy. Results for specific nutrients. *Ann Epidemiol*. 1996;6:110-
315 118.
- 316 **21.** Bravi F, Polesel J, Garavello W, et al. Adherence to the World Cancer Research Fund/American
317 Institute for Cancer Research recommendations and head and neck cancers risk. *Oral Oncol*.
318 2017;64:59-64.
- 319 **22.** Turati F, Bravi F, Polesel J, et al. Adherence to the Mediterranean diet and nasopharyngeal cancer
320 risk in Italy. *Cancer Causes Control*. 2017;28:89-95.
- 321 **23.** Bosetti C, La Vecchia C, Talamini R, et al. Food groups and risk of squamous cell esophageal cancer
322 in northern Italy. *Int J Cancer*. 2000;87:289-294.
- 323 **24.** Pelucchi C, Tramacere I, Bertuccio P, Tavani A, Negri E, La Vecchia C. Dietary intake of selected
324 micronutrients and gastric cancer risk: an Italian case-control study. *Ann Oncol*. 2009;20:160-165.
- 325 **25.** Lucenteforte E, Scita V, Bosetti C, Bertuccio P, Negri E, La Vecchia C. Food groups and alcoholic
326 beverages and the risk of stomach cancer: a case-control study in Italy. *Nutr Cancer*. 2008;60:577-
327 584.
- 328 **26.** Salvini S, Parpinel M, Gnagnarella P, Maisonneuve P, Turrini A. Banca di composizione degli
329 alimenti per studi epidemiologici in Italia. Milano, Italia: Istituto Europeo di Oncologia; 1998.
- 330 **27.** Gnagnarella P, Parpinel M, Salvini S, Franceschi S, Palli D, Boyle P. The update of the of the Italian
331 food composition database. *J Food Comp Anal*. 2004;17:502-5022.
- 332 **28.** Westenbrink S, Oseredczuk M, Castanheira I, Roe M. Food composition databases: the EuroFIR
333 approach to develop tools to assure the quality of the data compilation process. *Food chemistry*.
334 2009;113:759-767.
- 335 **29.** Fiori F, Concina F, Turati F, et al. Quantification of naturally occurring prebiotic fiber in Italian
336 foods. *Journal of Food Composition and Analysis*. 2022;112:104678.
- 337 **30.** Bertuccio P, Edefonti V, Bravi F, et al. Nutrient dietary patterns and gastric cancer risk in Italy.
338 *Cancer Epidemiol Biomarkers Prev*. 2009;18:2882-2886.
- 339 **31.** Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and
340 survival in a Greek population. *N Engl J Med*. 2003;348:2599-2608.
- 341 **32.** SAS, version 9.4. SAS Institute Inc., Cary, NC, USA.

- 342 **33.** Turati F, Concina F, Rossi M, et al. Association of prebiotic fiber intake with colorectal cancer risk:
343 the PrebiotiCa study. *Eur J Nutr.* 2022.
- 344 **34.** Turati F, Concina F, Bertuccio P, et al. Intake of prebiotic fibers and the risk of laryngeal cancer: the
345 PrebiotiCa study. *Eur J Nutr.* 2022:In press.
- 346 **35.** Leclercq C, Arcella D, Piccinelli R, et al. The Italian National Food Consumption Survey INRAN-
347 SCAI 2005-06: main results in terms of food consumption. *Public Health Nutr.* 2009;12:2504-2532.
- 348 **36.** Aune D, De Stefani E, Ronco A, et al. Legume intake and the risk of cancer: a multisite case-control
349 study in Uruguay. *Cancer Causes Control.* 2009;20:1605-1615.
- 350 **37.** Stojanovic J, Giraldi L, Arzani D, et al. Adherence to Mediterranean diet and risk of gastric cancer:
351 results of a case-control study in Italy. *Eur J Cancer Prev.* 2017;26:491-496.
- 352 **38.** Zhang XF, Wang XK, Tang YJ, et al. Association of whole grains intake and the risk of digestive
353 tract cancer: a systematic review and meta-analysis. *Nutr J.* 2020;19:52.
- 354 **39.** De Stefani E, Deneo-Pellegrini H, Mendilaharsu M, Ronco A. Diet and risk of cancer of the upper
355 aerodigestive tract--I. Foods. *Oral Oncol.* 1999;35:17-21.
- 356 **40.** La Vecchia C, Chatenoud L, Negri E, Franceschi S. Session: whole cereal grains, fibre and human
357 cancer wholegrain cereals and cancer in Italy. *Proc Nutr Soc.* 2003;62:45-49.
- 358 **41.** Giraldi L, Panic N, Cadoni G, Boccia S, Leoncini E. Association between Mediterranean diet and
359 head and neck cancer: results of a large case-control study in Italy. *Eur J Cancer Prev.* 2017;26:418-
360 423.
- 361 **42.** Gaesser GA. Whole Grains, Refined Grains, and Cancer Risk: A Systematic Review of Meta-
362 Analyses of Observational Studies. *Nutrients.* 2020;12.
- 363 **43.** Messina MJ. Legumes and soybeans: overview of their nutritional profiles and health effects. *Am J*
364 *Clin Nutr.* 1999;70:439S-450S.
- 365 **44.** Willett W, Stampfer MJ. Total energy intake: implications for epidemiologic analyses. *Am J*
366 *Epidemiol.* 1986;124:17-27.

367 **Figure legend**

368

369 **Figure 1.** Odds ratios^a (OR) of stomach cancer, and corresponding 95% confidence intervals (CI),
370 for the highest (T3) compared to the lowest tertile (T1) of raffinose intake in strata of age, sex,
371 education, body mass index (BMI), smoking status, and adherence to the Mediterranean diet among
372 230 cases of stomach cancer and 547 controls.

373

374

375

376 Footnotes of Figure 1.

377 ^a Adjusted for sex, age, study center, year of interview, education, alcohol drinking, tobacco
378 smoking, body mass index, adherence to the Mediterranean diet, and total energy intake unless the
379 variable was the stratification factor. Tests for effect modification were performed considering all
380 the tertiles of raffinose intake.

381 ^b The sum may do not add up to the total because of missing values.

Table 1. Italian case-control studies on cancers of the oral cavity and pharynx, nasopharynx, esophagus and stomach contributing to the present analysis.

Cancer site	Study period	Italian areas of study conduction	Total		Cases		Controls	
			N cases/N controls	N cases/N controls	N (M ^a /W ^b)	Age (yrs ^c), median [IQR ^d]	N (M ^a /W ^b)	Age (yrs ^c), median [IQR ^d]
Oral cavity and pharynx	1992-2009	Milan, Pordenone, Rome/Latina	946/2492	946/2492	756/190	58 [52-66]	1497/995	58 [50-66]
Nasopharynx	1992-2008	Milan, Pordenone, Naples, Catania	198/594	198/594	157/41	52 [43-62]	471/123	52 [43-63]
Esophagus	1992-1997	Milan, Pordenone, Padua	304/743	304/743	275/29	60 [54.5-66]	593/150	60 [54-67]
Stomach	1997-2007	Milan	230/547	230/547	143/87	63 [53-69]	286/261	63 [53-69]

^a M=men.^b W=women.^c yrs=years.^d IQR=interquartile range.

Table 2. Number of cancer cases, adjusted odds ratios^a (OR) and corresponding 95% confidence intervals (CI) of cancers of the upper digestive tract and stomach according to quantile of prebiotic fiber intake^b in the Italian network of case-control studies. Italy, 1992-2009.

	Oral cavity and pharynx		Nasoopharynx		Esophagus		Stomach	
	N (%)	Adjusted OR (95% CI)	N (%)	Adjusted OR (95% CI)	N (%)	Adjusted OR (95% CI)	N (%)	Adjusted OR (95% CI)
Inulin-type fructans								
I	227 (24.0)	1	58 (29.3)	1	85 (28.0)	1	67 (29.1)	1
II	223 (23.6)	1.1 (0.8-1.4)	58 (29.3)	0.9 (0.6-1.4)	119 (39.1)	1.4 (0.9-2.0)	73 (31.7)	1.0 (0.6-1.4)
III	227 (24.0)	1.2 (0.9-1.5)	82 (41.4)	1.1 (0.7-1.7)	100 (32.9)	1.3 (0.9-2.0)	90 (39.1)	1.1 (0.7-1.6)
IV	269 (28.4)	1.3 (0.97-1.7)	-	-	-	-	-	-
<i>P for trend</i>		0.071		0.662		0.207		0.700
1-STD ^c increase in log-transformed variable		1.1 (0.98-1.2)		1.1 (0.9-1.3)		1.2 (1.04-1.4)		0.9 (0.8-1.1)
Kestose (FOS^d)								
I	265 (28.0)	1	48 (24.2)	1	133 (43.8)		63 (27.4)	1
II	204 (21.6)	0.8 (0.6-1.06)	67 (33.8)	1.2 (0.7-1.9)	79 (26.0)	0.6 (0.4-0.97)	81 (35.2)	1.0 (0.6-1.5)
III	216 (22.8)	1.0 (0.7-1.3)	83 (41.9)	1.4 (0.8-2.3)	92 (30.3)	0.8 (0.5-1.2)	86 (37.4)	0.9 (0.5-1.4)
IV	261 (27.6)	1.0 (0.8-1.4)	-	-	-	-	-	-
<i>P for trend</i>		0.651		0.260		0.220		0.609
1-STD ^c increase in log-transformed variable		1.0 (0.9-1.1)		1.2 (0.98-1.5)		1.0 (0.8-1.2)		0.8 (0.7-1.0)
Nystose (FOS^d)								
I	208 (22.0)	1	45 (22.7)	1	106 (34.9)		60 (26.1)	1
II	228 (24.1)	1.1 (0.8-1.4)	67 (33.8)	1.2 (0.8-2.0)	93 (30.6)	1.0 (0.6-1.4)	83 (36.1)	1.0 (0.6-1.6)
III	244 (25.8)	1.2 (0.9-1.6)	86 (43.4)	1.6 (0.9-2.5)	105 (34.5)	0.9 (0.6-1.3)	87 (37.8)	0.9 (0.6-1.5)
IV	266 (28.1)	1.1 (0.8-1.4)	-	-	-	-	-	-
<i>P for trend</i>		0.450		0.084		0.483		0.626
1-STD ^c increase in log-transformed variable		1.1 (0.95-1.2)		1.2 (0.9-1.4)		0.9 (0.8-1.1)		0.9 (0.7-1.1)
1F-β-fructofuranosylnystose (FOS^d)								
I	318 (33.6)	1	66 (33.3)	1	130 (42.8)	1	58 (25.2)	1
II	235 (24.8)	1.0 (0.8-1.3)	66 (33.3)	0.9 (0.6-1.3)	97 (31.9)	1.0 (0.7-1.4)	87 (37.8)	1.4 (0.9-2.1)
III	153 (16.2)	0.8 (0.6-1.0)	66 (33.3)	0.8 (0.5-1.2)	77 (25.3)	0.8 (0.6-1.2)	85 (37.0)	1.2 (0.8-1.8)
IV	240 (25.4)	1.0 (0.8-1.3)	-	-	-	-	-	-
<i>P for trend</i>		0.755		0.250		0.365		0.589
1-STD ^c increase in log-transformed variable		1.0 (0.9-1.1)		1.0 (0.8-1.2)		1.0 (0.8-1.2)		1.2 (1.0-1.4)
Total FOS^{d,e}								

	Oral cavity and pharynx		Nasopharynx		Esophagus		Stomach	
	N (%)	Adjusted OR (95% CI)	N (%)	Adjusted OR (95% CI)	N (%)	Adjusted OR (95% CI)	N (%)	Adjusted OR (95% CI)
I	199 (21)	1	45 (22.7)	1	132 (43.4)	1	60 (26.1)	1
II	220 (23.3)	1.9 (0.7-1.2)	71 (35.9)	1.4 (0.9-2.3)	75 (24.7)	0.6 (0.4-0.9)	86 (37.4)	1.1 (0.7-1.7)
III	228 (24.1)	0.9 (0.7-1.3)	82 (41.4)	1.4 (0.8-2.5)	97 (31.9)	0.8 (0.5-1.2)	84 (36.5)	0.9 (0.5-1.4)
IV	299 (31.6)	1.01 (0.8-1.4)	-	-	-	-	-	-
<i>P for trend</i>		0.857		0.233		0.230		0.472
1-STD ^c increase in log-transformed variable Raffinose (GOS ^f)		1.0 (0.9-1.1)		1.2 (0.98-1.6)		1.0 (0.8-1.2)		0.8 (0.7-1.0)
I	266 (28.1)	1	47 (23.7)	1	133 (43.8)	1	66 (28.7)	1
II	233 (24.6)	1.0 (0.7-1.2)	73 (36.9)	1.4 (0.9-2.2)	84 (27.6)	0.7 (0.5-1.0)	93 (40.4)	1.0 (0.6-1.5)
III	205 (21.7)	0.9 (0.7-1.2)	78 (39.4)	1.3 (0.8-2.2)	87 (28.6)	0.8 (0.5-1.2)	71 (30.9)	0.6 (0.3-0.9)
IV	242 (25.6)	1.1 (0.8-1.5)	-	-	-	-	-	-
<i>P for trend</i>		0.768		0.334		0.193		0.019
1-STD ^c increase in log-transformed variable Stachyose (GOS ^f)		1.0 (0.9-1.1)		1.2 (0.96-1.5)		0.9 (0.8-1.1)		0.8 (0.6-0.99)
I	237 (25.1)	1	64 (32.3)	1	100 (32.9)		76 (33.0)	1
II	249 (26.3)	1.1 (0.9-1.4)	75 (37.9)	1.1 (0.7-1.7)	97 (31.9)	1.1 (0.8-1.6)	83 (36.1)	1.1 (0.7-1.6)
III	232 (24.5)	1.0 (0.8-1.4)	59 (29.8)	0.9 (0.5-1.4)	107 (35.2)	1.2 (0.8-1.8)	71 (30.9)	0.8 (0.5-1.2)
IV	228 (24.1)	1.1 (0.9-1.5)	-	-	-	-	-	-
<i>P for trend</i>		0.422		0.481		0.320		0.342
1-STD ^c increase in log-transformed variable		1.1 (0.98-1.2)		1.0 (0.8-1.2)		1.2 (0.98-1.4)		1.0 (0.8-1.2)

^a Adjusted for sex, age, study center, year of interview, education, alcohol drinking, tobacco smoking, body mass index, adherence to the Mediterranean diet, and total energy intake.

^b Derived among controls.

^c STD, standard deviation. The Table provides the OR for an increment of prebiotic intake equal to 1, calculated after a log-transformation of the prebiotic variables.

^d FOS=fructooligosaccharide.

^e Total FOSs was calculated as the sum of nystose, kestose and 1F- β -fructofuranosyl nystose.

^f GOS=galactooligosaccharides.

